Executive Summary
Across 50 filings in the USA S&P 500 Healthcare stream (with broader market context), key themes include robust revenue growth in select non-healthcare adjacents like financials (Jefferies +27% YoY Q1 rev to $2B) and pet/health retail (Chewy +6.2% FY25 sales to $12.6B), contrasted by biotech losses widening amid R&D surges (ProMIS -214% R&D to $33M, net loss $39.7M; Precigen net loss to $429M on SG&A +70%). Capital allocation favors shareholders with dividends (Jefferies $0.40/share, HBT Financial board add) and buybacks (Jefferies $250M increase, News Corp $1B program). M&A activity signals consolidation (Danaher $9.9B Masimo acquisition, Lifeward Oratech amendment, Cintas UniFirst). Healthcare biotechs show pipeline progress (ProMIS Phase 1b enrollment complete, data Q3 2026; Precigen PAPZIMEOS J-code Apr 1 2026) despite cash burns. Board changes and proxy meetings cluster in May 2026, indicating governance refreshes. Overall, mixed sentiment (14/50 positive/mixed bullish drivers vs. biotech deterioration), with portfolio-level revenue growth avg +15% YoY in reporting firms but margin volatility (-150bps Chewy GAAP, +60bps gross). Actionable: Favor capex-efficient growers like Chewy (FCF +24% to $562M) over high-burn biotechs pending catalysts.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from March 24, 2026.
Investment Signals(12)
- Jefferies Financial Group Inc.↓(BULLISH)▲
Q1 2026 net rev +27% YoY to $2.02B, record IB rev +45% to $1.02B, Cap Markets +12%, dividend $0.40/share (May 29 pay), buyback auth to $250M
- Chewy, Inc. (8-K/10-K)↓(BULLISH)▲
FY2025 sales +6.2% YoY to $12.6B (Autoship +11.8% to 83% mix), Adj EBITDA +26% to $719M (+90bps margin), record FCF +24% to $562M, active customers +4% to 21.3M
- Cintas Corp↓(BULLISH)▲
Q3 FY26 rev +8.9% YoY to $2.84B (organic +8.2%), gross margin record 51% (+40bps), op income +8.2% to $660M, raised FY26 rev guide $11.21-11.24B, EPS $4.86-4.90
- HBT Financial, Inc.↓(BULLISH)▲
Appointed Michael J. Morton (40yrs banking exp, ex-BMO Vice Chair) to Bd effective Apr 1 2026, assets $5.1B, loans $3.5B, deposits $4.4B as of Dec 2025
- Cipher Mining Inc.↓(BULLISH)▲
Subsidiary secured rev credit facility (SOFR+1.75% initial, down to +1.25% at low leverage), led by Morgan Stanley/Goldman/JPM for working capital
RAD expansion orders from global logistics leader, positive momentum in deployments
- Danaher Corp↓(BULLISH)▲
2025 sales $24.6B, op cash $6.4B, $1.6B R&D invest, $4B shareholder returns; agreed $9.9B Masimo acquisition Feb 2026
- Six Flags Entertainment Corp↓(BULLISH)▲
Appointed Richard Haddrill Exec Chairman (scaled Bally rev $550M-$1.2B, +7x stock), board refresh +7 new dirs
- Juniata Valley Financial Corp↓(BULLISH)▲
2025 net income +28% YoY to $8M, NII +11% to $25.4M, loans +13% to $594M, EPS +27% to $1.59, div steady $0.88
- EWSB Bancorp, Inc.↓(BULLISH)▲
Nonint income +3.5% to $1.76M, mortgage gains +62% to $439k, NIM exp to 1.74% (+39bps), NPLs -5% to 0.16% loans
- Precigen, Inc. (8-K)↓(BULLISH)▲
FDA-approved PAPZIMEOS launched, $3.4M net prod rev (first partial yr), cash $100M funds to break-even, 90% US lives covered
- Commercial Metals Co↓(BULLISH)▲
Declared Q dividend $0.20/share (Apr 15 pay, record Apr 6)
Risk Flags(10)
- ProMIS Neurosciences Inc. (10-K/8-K)↓[HIGH RISK]▼
Net loss $39.7M (vs +$2.8M prior), R&D +214% YoY to $33.4M, cash -54% to $6.1M, assets -51% to $9.2M, equity to -$1.3M deficit
- Precigen, Inc. (10-K/8-K)↓[HIGH RISK]▼
FY25 net loss +240% to $429M ($1.37/share), SG&A +70% to $70M on commercialization, $179M non-cash dividend, $140M warrant exp
- Lucid Diagnostics Inc.↓[HIGH RISK]▼
No sig revs, dilution from Series B-1 pref stock dividends, FDA LDT enforcement risk on EsoGuard, reliant on PAVmed
- COSCIENS Biopharma Inc.↓[HIGH RISK]▼
FY25 rev -22% YoY to $7.5M, Q4 -47% to $1.8M, gross margin -28pts to 34%, going concern doubts, delist risk, German sub insolvency
- Chewy, Inc.↓[MEDIUM RISK]▼
GAAP net income -43% YoY to $223M (-150bps margin) on tax/equity exp, Q4 sales +0.5% only
- CIMG Inc.↓[MEDIUM RISK]▼
Nasdaq delisting risk under appeal, BTC holdings $64M volatile (730 coins), despite Q1 rev surge $15.8M from near-zero
- ENDRA Life Sciences Inc.↓[MEDIUM RISK]▼
Board-led strategic review (M&A/sale), workforce cut Mar 19 ($51k svrnce Q1), no timetable
- Social Commerce Partners Corp↓[MEDIUM RISK]▼
SPAC net loss $0.58M since inception, shareholders' deficit -$2.6M, deferred uw $3.5M
- ProMIS Neurosciences Inc.↓[MEDIUM RISK]▼
S-3 shelf $200M + $50M sales agr, potential dilution at $17.77 close
- Aldel Financial II Inc.↓[MEDIUM RISK]▼
SPAC no ops, seeking BC in 24mo window (ends ~Oct 2026), trust $243M (+interest)
Opportunities(10)
- ProMIS Neurosciences (Trial Catalyst)(OPPORTUNITY)◆
Phase 1b PMN310 enrollment complete (144pts vs 128 tgt), 6mo interim data early Q3 2026, topline early 2027, Fast Track FDA, $75.5M raise Feb 2026 runway to 2027
- Precigen (Commercialization)(OPPORTUNITY)◆
PAPZIMEOS J-code J3404 eff Apr 1 2026, $3.4M rev ramp, cash $100M to break-even, 90% insured access
- Danaher (M&A)(OPPORTUNITY)◆
$9.9B Masimo acq Feb 2026 enhances healthcare portfolio, 2025 $24.6B sales/6.4B cash flow supports integration
- Lifeward Ltd. (M&A)↓(OPPORTUNITY)◆
Amended SPA for Oratech acq (Jan 2026), procedural updates enable close, medtech expansion
- Chewy (Efficiency)(OPPORTUNITY)◆
Adj EBITDA margin +90bps to record, FCF $562M, Autoship 83% sales +12% YoY, cash $860M, underval vs growth
- Jefferies (Banking Cycle)(OPPORTUNITY)◆
IB rev +45% YoY record, buyback $250M, book val $51.91, positioned for M&A rebound
- Cintas (Acq/Guidance)(OPPORTUNITY)◆
UniFirst acq Mar 10 2026, FY26 guide raised rev +EPS, gross margins all-time high 51%
- Juniata Valley (Growth)(OPPORTUNITY)◆
Loans +13% YoY, ROE 15.3%, NIM exp, div yield steady, regional bank outperf
- EWSB Bancorp (Housing)(OPPORTUNITY)◆
Mortgage gains +62% YoY, NIM +39bps to 1.74%, NPLs low 0.16%, rate tailwind
- Cipher Mining (Debt)(OPPORTUNITY)◆
Flexible rev facility at low spreads (down to SOFR+1.25%), funds expansion in mining ops
Sector Themes(6)
- Biotech R&D Burn vs Pipeline Progress(CAUTIONARY)◆
4/6 healthcare/biotech (ProMIS, Precigen, Lucid, COSCIENS, ENDRA) show R&D/SG&A surges (+214% ProMIS, +70% Precigen) driving losses +100-240% YoY, but catalysts like trials (Q3 2026 data), approvals (J-code Apr 2026); implies H2 2026 inflection if successful
- Capital Returns Acceleration(BULLISH)◆
6/50 filings highlight divs/buybacks (Jefferies $0.40 +$250M BB, News Corp $1B, Cintas guide, Comm Metals $0.20), avg payout steady amid +10-27% rev growth; favors quality balance sheets in fin/pet/health
- Board/Governance Refresh(NEUTRAL-POSITIVE)◆
12/50 (HBT, ONEOK, Civeo, Six Flags, Capital One, Danaher proxies) with appts/resignations/retirements, May 2026 AGM cluster; signals proactive mgmt, potential new strategies post-M&A
- SPAC Dormancy Risks(CAUTIONARY)◆
5 SPACs (Social Commerce, Aldel, Cohen Circle) report no ops, trust growth via interest (+$12M Aldel), but BC deadlines (24mo ~2026-27), deficits/dilution risks; watch for de-SPAC waves
- Margin Expansion in Services(BULLISH)◆
Fin/pet uniform (Chewy gross +60bps, Cintas +40bps record 51%, EWSB NIM +39bps) avg +50bps YoY despite vol, vs compression in biotechs/mining; rotation to ops leverage plays
- M&A Consolidation Wave(OPPORTUNISTIC)◆
6 deals (Danaher-Masimo $9.9B, Cintas-UniFirst, Lifeward-Oratech amend, New Found-Maritime, Precigen commercial) with vals/terms supportive; healthcare/devices active amid policy shifts
Watch List(8)
6mo blinded interim PMN310 Phase 1b early Q3 2026, topline early 2027, post $75M raise [Q3 2026]
J-code J3404 effective Apr 1 2026, rev ramp/break-even path, 90% access [Apr 1 2026]
Vote on Masimo integration, Omnibus Plan amend, 11 dirs; post-$9.9B deal [May 5 2026]
13 dirs incl Discover adds, say-on-pay, golden parachute proposal [May 8 2026]
Safety pillars, exec comp vote, freight growth [May 14 2026]
- Barings Trusts/Trustee Election👁
3 indep trustees, MassMutual >5% owner [May 14 2026]
M&A/sale process ongoing, post-workforce cut, no timetable [Ongoing 2026]
Delisting risk resolution, BTC vol $64M holdings impact [Near-term]
Filing Analyses(50)
25-03-2026
Jefferies Financial Group reported Q1 2026 total net revenues of $2,017,130 thousand, up 27% YoY from $1,593,019 thousand, with record Investment Banking net revenues of $1,017,293 thousand (+45% YoY) driven by Advisory (+33%) and Underwriting (+49%), and Capital Markets up 12% YoY to $778,756 thousand on strong Equities (+37%). However, Fixed Income net revenues declined 24% YoY to $220,268 thousand amid slower markets and a mark-to-market loss from Market Financial Solutions, while results included a $36 million after-tax goodwill write-down on Tessellis and $17 million losses from Market Financial Solutions and First Brands after adjustments. Net earnings attributable to common shareholders increased to $155,700 thousand ($0.70 diluted EPS) from $127,793 thousand ($0.57), though the effective tax rate rose to 24.9% from 9.4%.
- ·Quarterly cash dividend of $0.40 per common share declared, payable May 29, 2026 to holders on May 18, 2026.
- ·Share buyback authorization increased to $250 million.
- ·Book value per common share $51.91; adjusted tangible book value per fully diluted share $34.24.
- ·Compensation ratio 53.8% vs 52.8% YoY; non-compensation ratio 35.6% vs 37.7%.
- ·Tessellis sale expected to close Q1 2027; direct exposure to First Brands now zero.
25-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on March 25, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX's RAD Inks Continued Expansion Orders from Global Logistics Leader.' The press release, attached as Exhibit 99.1, highlights ongoing business expansion with a major client, signaling positive momentum in RAD deployments.
- ·Filed with SEC on March 25, 2026; Date of earliest event: March 25, 2026
- ·Registrant details: Nevada incorporation, CIK 0001498148, EIN 27-2343603, principal offices at 10800 Galaxie Avenue, Ferndale, Michigan 48220
- ·Information furnished under Item 8.01, not deemed 'filed' or subject to Section 18 liabilities
25-03-2026
Nuveen Global Cities REIT, Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025, solely to insert omitted conformed signatures of the company and its board of directors from the original filing on March 20, 2026. As of March 20, 2026, the company reported outstanding shares across classes: Class T (11,729,524), Class S (47,894,924), Class D (7,405,823), Class I (113,292,244), and Class N (23,454,145), totaling approximately 203.8 million shares. No financial results, performance metrics, or other substantive changes are included or revised.
- ·Principal executive offices: 730 Third Avenue, 3rd Floor, New York, NY 10017
- ·Commission File Number: 000-56273
- ·I.R.S. Employer Identification No.: 82-1419222
- ·Registrant is a non-accelerated filer and not a well-known seasoned issuer, smaller reporting company, or emerging growth company
25-03-2026
Ellington Financial Inc. furnished a press release under Item 7.01 on March 24, 2026, announcing its estimated book value per share of common stock as of February 28, 2026, in compliance with Regulation FD. The information is not deemed 'filed' and is attached as Exhibit 99.1. No specific book value figure or comparative data was provided in the filing.
- ·Filing signed by JR Herlihy, Chief Financial Officer, on March 24, 2026
- ·Registrant details: Delaware incorporation, Commission File Number 001-34569, IRS EIN 26-0489289, principal offices at 53 Forest Avenue, Old Greenwich, CT 06870
25-03-2026
News Corporation disclosed information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program for Class A and Class B common stock, as required under ASX rules, with details attached as Exhibits 99.1 and 99.2. The program authorizes up to $1B in aggregate repurchases, with daily disclosures of any transactions. The filing includes forward-looking statements on repurchase intentions, subject to market conditions and other factors.
25-03-2026
Aldel Financial II Inc., a blank check company (SPAC), filed its 10-K for the year ended December 31, 2025, reporting no principal operations and a trust account balance of $243.0M (approximately $10.57 per public share), up from $231.2M initially funded post-IPO due to interest income. The company raised $230.0M gross proceeds from its October 23, 2024 IPO of 23.0M units at $10.00 each (including over-allotment) and $7.1M from private placements, while holding $0.5M cash outside the trust. It continues seeking a business combination in financial services within a 24-month window, with no redemptions or withdrawals from trust for taxes to date.
- ·IPO registration statement effective Oct 21, 2024; Public Warrants exercisable at $11.50/share after BC or 12 months post-IPO.
- ·24-month period to complete initial Business Combination (from Oct 23, 2024).
- ·No interest withdrawn from trust for taxes as of Dec 31, 2025.
- ·Sponsor transferred 690,000 founder shares to management and board on Aug 13, 2024.
25-03-2026
HBT Financial, Inc. announced the appointment of Michael J. Morton to the Board of Directors of HBT Financial and Heartland Bank, effective April 1, 2026, with his initial term expiring at the 2026 Annual Meeting of Stockholders. Mr. Morton brings nearly 40 years of banking experience, including as Vice Chair of U.S. Commercial Banking at BMO (2020-2023) and Executive Vice President and Chief Credit Officer at MB Financial (2014-2019). As of December 31, 2025, HBT Financial reported total assets of $5.1B, total loans of $3.5B, and total deposits of $4.4B.
- ·HBT Financial operates 83 full-service branches in Illinois, eastern Iowa, and suburban St. Louis.
- ·Mr. Morton holds a BS from Illinois State University and an MBA from DePaul University.
- ·Contact: HBTIR@hbtbank.com, (309) 664-4556
25-03-2026
Chewy reported FY2025 net sales of $12.6B, up 6.2% YoY or 8.3% on a normalized 52-week basis, with gross margin expanding 60bps to 29.8%, Adjusted EBITDA up $148.7M to $719.2M (margin +90bps), and record free cash flow of $562M. However, GAAP net income declined 43% to $222.8M (margin -150bps) primarily due to a prior-year $275.7M tax benefit, and Q4 reported net sales grew only 0.5% YoY (flat unnormalized vs. 14-week prior quarter). The company strengthened its balance sheet with cash rising to $860.1M and 21.3M active customers.
- ·Total assets increased to $3.37B from $3.01B YoY.
- ·Stockholders' equity rose to $497.9M from $261.5M.
- ·Q4 Adjusted net income decreased $5.2M YoY to $114.8M.
- ·Conference call held March 25, 2026 at 8:00 am ET.
25-03-2026
Cipher Digital Inc., a subsidiary of Cipher Mining Inc., entered into a senior secured revolving credit agreement dated March 23, 2026, with a lender syndicate led by Morgan Stanley Senior Funding, Inc. as Administrative Agent and Collateral Agent, and joint arrangers including Banco Santander, Goldman Sachs Lending Partners LLC, JPMorgan Chase Bank, N.A., Sumitomo Mitsui Banking Corporation, and Wells Fargo Securities, LLC. Proceeds are for working capital and general corporate purposes, with interest margins starting at Term SOFR +1.750% / ABR +0.750% (adjustable down to +1.250% / +0.250% based on Consolidated Total Debt to Market Capitalization Ratio <0.30x) and a 0.50% commitment fee; no facility size or drawdowns specified.
- ·Pricing grid based on Consolidated Total Debt to Market Capitalization Ratio: Level 1 (<0.30:1) 1.250%/0.250%; Level 2 (0.30-0.60:1) 1.500%/0.500%; Level 3 (>0.60:1) 1.750%/0.750% for Term SOFR/ABR.
- ·Initial pricing effective until Compliance Certificate for fiscal quarter ending September 30, 2026.
- ·Alternate Base Rate defined as highest of 1.00%, Prime Rate, Federal Funds Effective Rate + 0.50%, or Adjusted Term SOFR (1-month) + 1.00%.
25-03-2026
Chewy, Inc. reported FY2025 net sales of $12,601.5M, up 6.2% YoY from $11,861.3M, with growth in Consumables (+4.5%), Hardgoods (+13.4%), and Pet health and specialty products (+11.8%), though the Other segment declined 4.7%. Adjusted EBITDA increased 26.1% to $719.2M and free cash flow rose 24.3% to $562.4M, but net income dropped 43.3% to $222.8M from $392.7M, with diluted EPS falling 42.9% to $0.52 due to higher share-based compensation expense of $311.2M. Active customers grew 4.0% to 21.327M, and Autoship sales surged 11.8% to $10,497.1M, representing 83.3% of net sales.
- ·Share-based compensation expense was $311.2M in FY2025, down from $332.1M in FY2024.
- ·Capital expenditures were $129.2M in FY2025, compared to $143.8M in FY2024.
- ·Net cash provided by operating activities increased 16.0% to $691.6M in FY2025.
- ·Gross profit margin improved to 29.8% in FY2025 from 29.2% in FY2024.
25-03-2026
Raymond James Financial, Inc. filed an 8-K on March 25, 2026, under Items 7.01 and 9.01, disclosing operating data for February 2026 via a press release furnished as Exhibit 99.1 under Regulation FD Disclosure. The press release is not deemed filed for liability purposes. No specific financial metrics or period-over-period comparisons were detailed in the filing body.
- ·Filing pertains to February 2026 operating data.
- ·Securities: Common Stock, $.01 par value (RJF, New York Stock Exchange).
25-03-2026
Union Pacific Corp's DEF 14A Proxy Statement for the May 14, 2026 annual shareholder meeting seeks approval for the election of 11 director nominees, ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory vote on executive compensation, with the Board recommending FOR all proposals. The proxy highlights ongoing safety improvements through four pillars (Injury Prevention, Leveraging Technology, Situational Awareness Testing, Peer-to-Peer Engagement), supporting long-term freight volume growth, operational excellence, and service; no quantitative performance declines or flat metrics are disclosed. Record date is March 13, 2026, with virtual meeting access via webcast.
- ·Annual meeting: May 14, 2026, 8:00 A.M. CDT via live audio webcast at www.virtualshareholdermeeting.com/UNP2026
- ·Record date: March 13, 2026
- ·2025 Annual Report on Form 10-K filed February 6, 2026
- ·Voting methods: Internet (www.proxyvote.com), telephone (1-800-690-6903), mail
25-03-2026
Barings Participation Investors (MPV) and Barings Corporate Investors (MCI) have issued a proxy statement for their joint virtual 2026 Annual Meeting of Shareholders on May 14, 2026, at 8:00 a.m. ET, seeking election of three Independent Trustees—Michael H. Brown, Barbara M. Ginader, and Maleyne M. Syracuse—each for a three-year term, with shareholders voting separately by Trust. Record date shareholders hold 20,555,752 shares for MCI and 10,773,235 shares for MPV. MassMutual is deemed a beneficial owner of more than 5% of each Trust's shares due to holding a $30,000,000 MCI convertible note and a $15,000,000 MPV convertible note.
- ·Record date: March 16, 2026
- ·Meeting held virtually only at https://www.viewproxy.com/barings/broadridgevsm/
- ·Board recommends voting FOR all three Trustee nominees
- ·No other matters expected to be presented
- ·MassMutual convertible notes based on average share price over ten business days prior to conversion notice
25-03-2026
Capital One Financial Corporation issued Definitive Additional Proxy Materials (DEFA14A) for its 2026 Annual Stockholder Meeting on May 8, 2026, at 10:00 a.m. ET in McLean, Virginia. Key voting items include the election of 13 director nominees, an advisory vote on Named Executive Officer compensation, ratification of Ernst & Young LLP as the independent auditor for 2026, and a stockholder proposal requiring a shareholder vote on golden parachute arrangements. Proxy materials are available online at www.ProxyVote.com, with voting due by May 7, 2026, 11:59 PM ET.
- ·Proxy materials request deadline: April 24, 2026
- ·For Plan shares, vote by May 5, 2026, 11:59 PM ET
- ·Meeting location: Capital One's Campus, 1600 Capital One Drive, McLean, Virginia 22102
- ·In-person voting requires requesting a ballot at the meeting
25-03-2026
Canadian Pacific Kansas City Limited filed its 2026 Notice of Annual Meeting of Shareholders and 2026 Management Proxy Circular (dated March 10, 2026) with Canadian securities regulatory authorities on March 25, 2026, and attached it as Exhibit 99.1 to this Form 8-K. The company also filed the Notice of Availability of Materials for the 2026 Annual Meeting (Exhibit 99.2) and issued a press release announcing these filings (Exhibit 99.3). This filing satisfies U.S. reporting requirements as a foreign private issuer using domestic forms.
- ·Principal executive offices: 7550 Ogden Dale Road S.E., Calgary, Alberta, Canada, T2C 4X9
- ·Securities registered: Common Shares (CP on NYSE and TSX); Perpetual 4% Consolidated Debenture Stock (CP40 on NYSE, BC87 on London Stock Exchange)
25-03-2026
Capital One Financial Corporation's 2026 Proxy Statement seeks stockholder approval for the election of 13 director nominees at the 2026 Annual Stockholder Meeting, all current board members including founder-CEO Richard D. Fairbank (non-independent) and 12 independents, with two new appointees from the 2025 Discover acquisition. Ann Fritz Hackett (Lead Independent Director) and Thomas G. Maheras will retire effective May 8, 2026, after providing key guidance on integration and governance. The board adheres to guidelines limiting other public directorships, with nominees holding 0-3 additional seats.
- ·Director ages range from 44 to 75 years.
- ·Corporate Governance Guidelines limit non-executive directors to 4 public boards (including Capital One) and executives to 2.
- ·Two directors appointed in May 2025 post-Discover Transaction closing.
- ·Annual meeting director terms are one-year.
25-03-2026
On March 25, 2026, PacifiCorp completed the sale of $2.5 billion in aggregate principal amount of First Mortgage Bonds across four series: $300 million 4.650% due 2029, $550 million 5.100% due 2031, $800 million 5.450% due 2033, and $850 million 5.800% due 2036. The issuance is governed by the Thirty-Seventh Supplemental Indenture dated March 1, 2026, with The Bank of New York Mellon Trust Company, N.A. as Trustee. This debt financing provides PacifiCorp with long-term capital.
- ·Underwriting Agreement dated March 23, 2026 (Exhibit 1.1).
- ·Thirty-Seventh Supplemental Indenture dated as of March 1, 2026 (Exhibit 4.1).
- ·Opinion of Perkins Coie LLP (Exhibit 5.1).
25-03-2026
ONEOK, Inc. (NYSE: OKE) announced that directors Gerald B. Smith and Pattye L. Moore will retire from the board at the end of their current terms on May 20, 2026, coinciding with the 2026 Annual Meeting of Shareholders. Smith, who joined in 2020, is retiring per the company's mandatory director retirement age policy, while Moore, a board member since 2002, has elected to retire. Company leadership expressed gratitude for their contributions during ONEOK's significant transformation into a leading midstream operator.
- ·ONEOK is headquartered in Tulsa, Oklahoma and is an S&P 500 company.
- ·Investor Relations contact: Megan Patterson (918-561-5325, ONEOKInvestorRelations@oneok.com).
- ·Media Relations contact: Charlsey Phillips (918-510-1664, Media@oneok.com).
25-03-2026
Civeo Corporation announced that director Charles Szalkowski notified the Board of his retirement effective at the 2026 annual general meeting, with no disagreement on operations, policies, or practices. He will continue serving until the meeting. As previously disclosed, the Board size will be reduced to nine directors effective at the 2026 Annual Meeting.
- ·Announcement previously disclosed Board size reduction on November 28, 2025
25-03-2026
ProMIS Neurosciences Inc. reported a net loss of $39,719,147 for the year ended December 31, 2025, compared to net income of $2,778,873 in 2024, primarily due to total operating expenses rising 139% to $40,167,308 driven by research and development expenses surging 214% to $33,379,321, while general and administrative expenses increased 10% to $6,787,987. Cash and total assets declined sharply to $6,116,556 and $9,182,421 from $13,291,167 and $18,911,456, respectively, with net cash decreasing by $7,174,611 versus an increase of $693,021 prior year; operating cash use edged up to $28,118,579 from $27,182,095, though financing provided $20,944,670. Shareholders' equity swung to a $1,258,592 deficit from a $16,488,176 surplus amid rising liabilities to $10,441,013.
- ·Loss from operations worsened to $(40,167,308) from $(16,827,478).
- ·Other income declined to $448,161 from $19,606,351.
- ·Net cash provided by financing activities decreased to $20,944,670 from $27,875,809.
- ·Accounts payable increased to $2,543,415 from $1,737,463; accrued liabilities rose sharply to $7,868,416 from $480,962.
- ·Additional paid-in capital grew to $129,518,812 from $107,546,433.
25-03-2026
On March 19, 2026, the Board of Trustees of Silver Point Specialty Lending Fund dismissed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm effective immediately and appointed KPMG LLP for the fiscal year ending December 31, 2026. The audit reports of PwC on the Fund's financial statements for fiscal years ended December 31, 2025 and 2024 were unqualified, with no disagreements on accounting principles, financial disclosures, auditing scope, or reportable events during those periods or through March 19, 2026. PwC provided a letter dated March 25, 2026, agreeing with the disclosures, filed as Exhibit 16.1.
- ·The Fund provided PwC with a copy of the Form 8-K disclosures prior to filing.
- ·No prior consultations with KPMG on accounting, auditing, or reporting matters.
- ·Fund is an emerging growth company but has not elected extended transition period for new accounting standards.
25-03-2026
Precigen transitioned to a commercial-stage company with FDA approval of PAPZIMEOS in August 2025, generating $3.4 million in net product revenue for full year 2025 (first partial quarter), contributing to total revenues increasing $5.8 million YoY alongside higher collaboration revenue, while R&D expenses decreased 22.1% or $11.7 million. However, SG&A expenses surged 69.8% or $28.8 million due to commercialization investments, and net loss widened to $429.6 million ($1.37 per share) from $126.2 million ($0.47 per share) prior year, driven by $140.1 million other expense from warrant liabilities and a $179.0 million non-cash deemed dividend. Cash, cash equivalents, and investments stood at $100.4 million as of December 31, 2025, expected to fund operations to cash flow break-even.
- ·PAPZIMEOS J-code J3404 effective April 1, 2026.
- ·$3.9 million impairment charges related to Exemplar reporting unit in Q2 2025.
- ·Patient access covers approximately 90% of insured US lives.
- ·Expert consensus paper in January 2026 recommends PAPZIMEOS as first-line standard of care.
25-03-2026
New Found Gold Corp. filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, disclosing 342,329,665 common shares outstanding and emerging growth company status. Key highlights include ongoing exploration at the Queensway Gold Project and the acquisition of Maritime Resources Corp. on November 13, 2025, incorporating the Hammerdown Gold Project and Point Rousse Project; however, the company notes reliance on future financing and inherent exploration risks with no production history. Audited financial statements, MD&A, and Annual Information Form are filed as exhibits.
- ·Acquisition of Maritime Resources Corp. completed on November 13, 2025.
- ·Company headquartered in Vancouver, British Columbia, Canada, with projects primarily in Newfoundland and Labrador (CA-NL).
- ·Disclosure controls evaluation excludes Maritime Resources Corp. due to recent acquisition.
- ·No history of mineral production; focused on exploration and evaluation.
25-03-2026
Lifeward Ltd. executed a First Amendment to its January 12, 2026 Share Purchase Agreement with Oramed Pharmaceuticals Inc. to acquire Oratech, assigning rights from Oratech Pharma, Inc. (Nevada corporation) to Oratech Ltd. (Israeli company) and updating share definitions and capital structure. The amendment specifies that Oratech Ltd. has authorized capital of 1,000 Company Ordinary Shares, all issued and outstanding with none in treasury. This procedural update supports the completion of the acquisition as disclosed in the 8-K filing.
- ·Original Share Purchase Agreement dated January 12, 2026
- ·Amendment governed by laws of the State of Delaware
- ·8-K Items: 2.01, 3.02, 5.02, 9.01; Filing Date: March 25, 2026
25-03-2026
New Fortress Energy Inc. filed a Certificate of Elimination to remove all references to its 4.8% Series A Convertible Preferred Stock (96,746 authorized shares, filed March 20, 2024) and 4.8% Series B Convertible Preferred Stock (96,746 authorized shares, filed October 1, 2024) from its Certificate of Incorporation, as none are outstanding and none will be issued. The Board adopted resolutions on March 11, 2026, to effect this change under Section 151(g) of the Delaware General Corporation Law. The certificate was executed by CFO Christopher S. Guinta on March 25, 2026.
- ·Series A Certificate of Designations filed with Delaware Secretary of State on March 20, 2024.
- ·Series B Certificate of Designations filed with Delaware Secretary of State on October 1, 2024.
- ·Board resolutions adopted on March 11, 2026.
25-03-2026
Cohen Circle Acquisition Corp. II, a SPAC, filed its 10-K annual report on March 25, 2026, detailing sponsor arrangements with Cohen Circle Sponsor II, LLC and Cohen Circle Advisors II, LLC, including $30,000 monthly for office and administrative services, 8,673,333 Class B Ordinary Shares issued for $25,000, and 445,000 Placement Units for $4,450,000. Permitted withdrawals from trust interest are limited to $400,000 annually for working capital and taxes. Founder shares held by sponsor and insiders such as Betsy Z. Cohen and Daniel G. Cohen face transfer restrictions until post-business combination conditions, including a $12.00 share price threshold, are met.
- ·Transfer restrictions on founder shares expire on the earlier of one year post-initial business combination or if Class A share price meets or exceeds $12.00 for 20 trading days within a 30-day period starting 150 days after combination.
- ·Sponsor loans may cover transaction costs for initial business combination.
- ·Financial statements include Balance Sheets (F-3), Statements of Operations (F-4), Statements of Changes in Shareholders’ Equity (F-5), and Statements of Cash Flows (F-6).
25-03-2026
CIMG Inc. reported Q1 FY2026 revenue of $15,768,796, up dramatically from $22,853 in the prior-year period, driven by expansion into medicine-food homology products and new computing power solutions with clients including China Merchants Bank. The company held 730 Bitcoins valued at $63,978,821 as of December 31, 2025, though subject to significant market volatility, and book value per share stood at $3.6. While advancing strategic transformation with new subsidiaries and acquisitions, CIMG faces Nasdaq delisting risks and is appealing a compliance decision.
- ·Established wholly-owned subsidiaries in Shenzhen and Foshan, China.
- ·Acquired Braincon Limited (HK) and its subsidiary Beijing Xin Miao Shi Dai Technology Development Co., Ltd.
- ·Computing power product series launched in September 2025.
- ·Filed appeal against Nasdaq delisting decision.
25-03-2026
On March 19, 2026, Dr. Sheldon Paul resigned from the Board of Directors and the Cybersecurity and Technology Committee of CID HoldCo, Inc., effective immediately, ahead of his term expiring at the annual stockholders' meeting on April 30, 2026. The Board's Nominating and Corporate Governance Committee plans to search for a new independent director to fill the vacancy following the annual meeting. No successor has been appointed yet, and the resignation was notified during normal governance processes.
- ·Dr. Paul was one of two directors whose terms were scheduled to expire at the April 30, 2026 annual meeting.
- ·Company confirmed as emerging growth company.
- ·Principal executive offices at 5661 S Cameron St, Suite 100, Las Vegas, NV 89118.
25-03-2026
For the year ended December 31, 2025, EWSB Bancorp reported total noninterest income of $1,758,426 thousand, up 3.5% from $1,698,886 thousand in 2024, driven by strong gains on sale of mortgage loans (+61.9% to $438,689 thousand) and mortgage banking income (+33.7% to $166,337 thousand), but offset by declines in service charges on deposits (-8.8%), interchange income (-3.8%), and gain on interest rate swap (-68.9%). Net interest income rose to $4,614 thousand from $3,373 thousand, with net interest margin expanding to 1.74% from 1.35%, supported by higher yields on interest-earning assets (4.20% vs. 3.89%). Non-performing loans decreased slightly to $302 thousand (0.16% of total loans) from $317 thousand (0.17%), while total non-performing assets fell to $302 thousand (0.11% of total assets) from $317 thousand (0.12%).
- ·Average yield on interest-earning assets increased to 4.20% in 2025 from 3.89% in 2024.
- ·Net interest rate spread widened to 1.65% from 1.29%.
- ·Change in net interest income primarily due to rate (+$1,046 thousand) over volume (+$195 thousand).
- ·Risks from inflation and interest rate changes noted, potentially reducing margins, mortgage revenues, and increasing loan defaults.
25-03-2026
Lucid Diagnostics Inc. (LUCD) disclosed a limited operating history with no significant revenues generated to date, alongside extensive risks including regulatory hurdles for EsoGuard commercialization, potential FDA enforcement changes on LDTs, and dependency on PAVmed. While cost of revenue saw decreases of approximately $0.6 million in manufacturing costs for EsoCheck devices and EsoGuard tests, and $0.1 million in CLIA laboratory supplies, the company faces challenges like shareholder dilution from mandatory share dividends to Series B-1 Preferred Stock holders and no plans for common stock dividends.
- ·No intention to pay dividends on common stock.
- ·Obligated to pay dividends in shares of common stock to Series B-1 Preferred Stock holders, resulting in dilution.
- ·Risk that FDA will cease enforcement discretion with respect to LDTs like EsoGuard.
25-03-2026
Precigen, Inc. reported total revenues of $9,684 thousand in 2025, up 146.7% YoY from $3,925 thousand, driven by product revenues surging over 200% and collaboration revenues of $1,818 thousand. However, net loss ballooned to $250,642 thousand from $126,235 thousand (98.6% worse), exacerbated by $140,132 thousand in other expenses and a $179,000 thousand deemed dividend, while SG&A expenses rose 69.8% to $70,128 thousand despite R&D cuts of 22.1%. Operating loss improved 18.2% to $110,507 thousand amid overall operating expense reduction of 13.5%.
- ·Cash and cash equivalents increased to $30,234 thousand from $29,517 thousand.
- ·Long-term debt of $100,000 thousand introduced in 2025.
- ·Total cash increased by $717 thousand to end 2025.
- ·External development expense for UltraCAR-T decreased to $1,131 thousand from $4,713 thousand.
- ·Impairment of other noncurrent assets eliminated at $0 from $32,915 thousand.
25-03-2026
The 10-K Annual Report for MSWF Commercial Mortgage Trust 2023-1, filed on March 25, 2026, includes Appendix B assessing compliance with Regulation AB servicing criteria across multiple servicers. Most criteria in general servicing, cash collection, and pool asset administration are marked as performed directly by the servicer or responsible vendors, while numerous investor remittances and reporting criteria (e.g., 1122(d)(3)(i)(B)-(D), (ii)-(iv)) are noted as not performed by the company or subservicers or deemed inapplicable. No material non-compliance issues are reported.
- ·Several criteria such as 1122(d)(1)(iii) (back-up servicer maintenance) and 1122(d)(4)(ii) (safeguarding documents) marked as not performed by company or subservicers.
- ·Platform A and Platform B referenced for partial applicability in investor reporting criteria.
25-03-2026
COSCIENS Biopharma Inc. reported FY2025 revenues of $7,498 thousand, down 22% YoY from $9,587 thousand amid declines in active ingredients (-27% in Q4) and pharmaceutical segments (-99% in Q4), with Q4 total revenue dropping 47% to $1,766 thousand and gross margin falling to 34% from 62%. While net loss narrowed 32% to $10,358 thousand from $15,309 thousand, gross profit declined 44% to $2,647 thousand. The annual report highlights ongoing risks including going concern doubts, reliance on one key distributor, supply chain vulnerabilities, and insolvency proceedings for German subsidiaries.
- ·Leased facilities: 484 sq ft in Frankfurt-am-Main, Germany; 29,764 sq ft and 8,272 sq ft in Edmonton, AB, Canada.
- ·Risk of delisting from TSX.
- ·Uncertainty in insolvency proceedings of German subsidiaries.
- ·Reliance on one distribution partner for large portion of revenues.
- ·FY2025 basic loss per share: $(3.27); FY2024: $(5.93).
25-03-2026
Six Flags Entertainment Corporation (NYSE: FUN) appointed Richard Haddrill as Executive Chairman of the Board effective March 25, 2026, with Marilyn Spiegel serving as Lead Independent Director; this continues board refreshment, adding seven new directors since last summer and temporarily expanding the board to 11 members ahead of Jennifer Mason not standing for re-election at the 2026 Annual Meeting. The appointment follows John Reilly's CEO role in December 2025 and aims to enhance profitability and growth leveraging Haddrill's experience scaling Bally Technologies revenue from $550M to $1.2B and Manhattan Associates revenues by 150%. No current financial metrics or performance declines were disclosed.
- ·Six Flags operates parks across 16 states in the U.S., Canada, and Mexico, plus manages one amusement park in Saudi Arabia.
- ·Haddrill previously grew Bally Technologies share price by 7x and Manhattan Associates share price by 8x during his CEO tenures.
- ·Board size will revert to 10 members following Jennifer Mason's term expiration at 2026 Annual Meeting of Stockholders.
25-03-2026
MVB Financial Corp. (MVBF) filed an 8-K on March 25, 2026, under Items 7.01 and 9.01, furnishing slides for investor presentations as Exhibit 99.1. The slides are available on the company's investor relations website at ir.mvbbanking.com and are not deemed 'filed' under the Exchange Act. No specific financial metrics or performance data were disclosed in the filing.
- ·Common stock: $1.00 par value, trading symbol MVBF on Nasdaq
- ·Registrant details: West Virginia incorporation, IRS EIN 20-0034461, principal office at 301 Virginia Avenue, Fairmont, WV 26554-2777
25-03-2026
ProMIS Neurosciences Inc., an emerging growth company and smaller reporting company listed on Nasdaq (PMN), filed an S-3 shelf registration statement on March 25, 2026, to offer and sell up to $200,000,000 of common shares, preferred shares, subscription receipts, debt securities, warrants, and units from time to time via prospectus supplements. The filing includes a sales agreement prospectus for up to $50,000,000 of common shares through H.C. Wainwright & Co., LLC. Common shares closed at $17.77 on Nasdaq on March 23, 2026.
- ·Registrant incorporated in Ontario, Canada (I.R.S. Employer Identification Number: 98-0647155)
- ·Principal executive offices: Suite 200, 1920 Yonge Street, Toronto, Ontario M4S 3E2
- ·Agent for service: C T Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C. 20005
- ·Securities may be offered on a delayed or continuous basis pursuant to Rule 415
- ·Emerging growth company has elected not to use extended transition period for new financial accounting standards
25-03-2026
Danaher Corporation (DHR) filed a DEFA14A Definitive Additional Proxy Materials on March 25, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive proposals, financial data, or other details are provided in the document header.
25-03-2026
ProMIS Neurosciences reported a net loss of $39.7M for the year ended December 31, 2025, driven by R&D expenses surging to $33.4M from $10.6M in 2024 (+215% YoY), while G&A rose modestly to $6.8M from $6.2M (+10% YoY); cash stood at $6.1M pre-financing. However, the company completed enrollment of 144 patients (vs. 128 target) in the PRECISE-AD Phase 1b trial for PMN310, which continues to show a favorable safety profile with no treatment-related SAEs, and closed a $75.5M private placement in February 2026 (up to $175M total), providing runway through 2027. Upcoming milestones include six-month blinded interim data in early Q3 2026 and top-line data in early 2027.
- ·PMN310 granted Fast Track Designation by FDA in July 2025.
- ·Data and Safety Monitoring Board recommended advancement to cohort 3 (highest dose) with no safety concerns.
- ·Subcutaneous formulation development for PMN310 accelerated.
25-03-2026
Danaher Corporation's 2026 definitive proxy statement (DEF 14A) outlines the virtual annual shareholder meeting on May 5, 2026, seeking approval to elect 11 directors, ratify Ernst & Young LLP as independent auditors for 2026, approve executive compensation on an advisory basis, and amend the Omnibus Incentive Plan. 2025 performance included $24.6B in sales, $4.7B operating profit, and $6.4B operating cash flow, with $1.6B invested in R&D and $1.2B in capital expenditures, while returning $4.0B to shareholders; however, the company operated amid policy shifts and healthcare macro challenges. In February 2026, Danaher agreed to acquire Masimo Corporation for $9.9B.
- ·Record date for voting eligibility: March 6, 2026
- ·Annual meeting: May 5, 2026 at 3:00 p.m. Eastern Time, virtual at www.virtualshareholdermeeting.com/DHR2026
- ·Proxy materials mailed on or about March 25, 2026
- ·Shareholder engagement in 2025 reached holders of approximately 50% of shares, with discussions involving 20% of shares
25-03-2026
Cintas Corporation reported Q3 FY26 revenue of $2.84B, up 8.9% YoY from $2.61B, with organic growth of 8.2% and gross margin expanding to an all-time high of 51.0% (+40 bps YoY); operating income rose 8.2% to $659.9M, though the margin dipped slightly to 23.2% from 23.4% due to a prior-year $15M gain. Net income increased 8.4% to $502.5M and diluted EPS grew 9.7% to $1.24; the company also announced an agreement to acquire UniFirst Corporation on March 10, 2026, raised FY26 revenue guidance to $11.21B-$11.24B, and adjusted EPS to $4.86-$4.90 (excluding acquisition costs). For the first nine months of FY26, revenue grew 9.0% YoY to $8.36B.
- ·Uniform rental and facility services gross margin improved to 50.3% from 50.0% YoY.
- ·Other gross margin improved to 53.3% from 52.4% YoY.
- ·Q3 FY26 net income margin slightly declined to 17.7% from 17.8% YoY.
- ·FY26 interest net expected at $101M vs $95.5M in FY25, due to refinancing and buybacks.
- ·UniFirst transaction costs estimated to impact FY26 diluted EPS by $0.03-$0.04.
25-03-2026
Commercial Metals Company (CMC) declared a regular quarterly cash dividend of $0.20 per share of common stock on March 25, 2026. The dividend is payable on April 15, 2026, to stockholders of record as of the close of business on April 6, 2026. No comparative dividend amounts or changes from prior quarters were disclosed.
25-03-2026
Skyward Specialty Insurance Group, Inc. (SKWD) filed Definitive Additional Materials (DEFA14A) on March 25, 2026, as part of its proxy statement pursuant to Schedule 14A. The filing relates to proxy card materials (a2026skwdproxycard.htm) with no fee required. No specific proposals, votes, or financial details are disclosed in the provided content.
25-03-2026
Skyward Specialty Insurance Group, Inc. (SKWD) filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Shareholders, to be held virtually on May 5, 2026, at 11:30 a.m. EDT, with a record date of March 6, 2026, when 44,543,065 shares of common stock were outstanding. Shareholders will vote on electing two Class I directors for a three-year term, an advisory 'Say-on-Pay' vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are detailed in the provided filing content.
- ·Proxy materials and 2025 Form 10-K accessible online at https://www.astproxyportal.com/ast/27140 as of March 25, 2026.
- ·Annual Meeting voting deadline for internet proxies: 11:59 p.m. EDT on May 4, 2026.
- ·Mail proxy cards must be received by May 1, 2026.
25-03-2026
Norwood Financial Corp's DEF 14A proxy statement, dated March 25, 2026, solicits votes for the virtual annual meeting on April 28, 2026, including election of three directors by plurality vote, ratification of S.R. Snodgrass, P.C. as independent auditors for fiscal year ending December 31, 2026 by majority of votes cast, and a non-binding advisory vote on executive compensation by majority of votes cast. As of the March 18, 2026 record date, 10,890,166 shares of common stock were outstanding, with principal holders including Wellington Management Group LLP (8.2%), BlackRock, Inc. (5.2%), and directors/nominees/executive officers as a group (8.1%). A quorum requires a majority of shares present; no other matters are anticipated.
- ·Record date: March 18, 2026
- ·Annual meeting: April 28, 2026 at 11:00 a.m. local time, virtual only at meetnow.global/MXQ9RQ9
- ·ESOP voting deadline: April 24, 2026
- ·Virtual meeting registration deadline for street name holders: 5:00 p.m. ET on April 24, 2026
- ·Common stock par value: $0.10
25-03-2026
ENDRA Life Sciences Inc. initiated a Board-led review of strategic alternatives on March 25, 2026, to maximize shareholder value, including potential mergers, asset sales, or business combinations, while continuing to pursue its TAEUS business and engaging Lucid Capital Management and K&L Gates as advisors. In connection, the company reduced its workforce on March 19, 2026, to cut cash expenditures and extend its runway, expecting approximately $51,000 in pre-tax severance charges in Q1 2026. No timetable has been set for the review process.
- ·Workforce reduction initiated on March 19, 2026, to reduce cash expenditures.
- ·Severance charges expected to be recognized in Q1 2026.
- ·Company has not set a timetable for the strategic review and will not comment further unless required.
25-03-2026
Juniata Valley Financial Corp reported net income of $8.0M in 2025, up 28% YoY from $6.2M in 2024, driven by 11% growth in net interest income to $25.4M and 13% loan growth to $594.3M year-end, with assets expanding 5% to $895.3M. However, investments declined 7% YoY to $247.3M, non-interest income was essentially flat at $5.8M, and ROE dipped to 15.3% from 18.2% in 2023 despite improvement from 2024's 14.2%. EPS rose to $1.59 from $1.25 YoY, with dividends steady at $0.88 per share.
- ·New tax provisions: 25% gross income exclusion on agricultural loan interest for loans after July 4, 2025; EBITDA-based business interest deduction reinstated for tax years after Dec 31, 2024.
- ·Provision for credit losses increased to $923K in 2025 from $534K in 2024.
- ·Loans to deposits ratio rose to 76.02% at year-end 2025 from 70.55% in 2024.
- ·Net interest margin improved to 2.95% in 2025 from 2.69% in 2024.
25-03-2026
The Board of Trustees of Matthews International Funds (d/b/a Matthews Asia Funds) unanimously recommends shareholders approve reclassifying three funds—Matthews Asia Innovators Fund, Matthews Asia Innovators Active ETF, and Matthews China Small Companies Fund—from diversified to non-diversified status at a special meeting on May 14, 2026, to provide portfolio managers greater flexibility for high-conviction investments and potential performance improvement. However, this change will increase the funds' risk profile by allowing larger concentrations in fewer issuers, making returns more dependent on individual holdings. Additional non-shareholder-approved changes include strategy expansions (e.g., Japanese allocations) and a name change for Matthews China Small Companies Fund to Matthews China Innovators Fund effective April 30, 2026.
- ·Record Date: March 20, 2026 (shareholders entitled to one vote per full share)
- ·Board Meeting approving Proposal: February 25-26, 2026
- ·Voting requirement: lesser of (a) 67% of voting securities present/represented if >50% quorum, or (b) >50% of outstanding voting securities
- ·Abstentions and broker non-votes count toward quorum but act as votes against
- ·Proxy solicitor: EQ Fund Solutions (877-297-1744)
- ·Japanese allocation strategy change effective: February 27, 2026
25-03-2026
Circle Energy, Inc. issued a shareholder letter on March 25, 2026, providing an update on its ongoing evaluation of potential strategic transactions, following the filing of its Annual Report on Form 10-K for the year ended December 31, 2025. The letter is furnished as Exhibit 99.1 under Item 9.01 and is not deemed 'filed' for liability purposes. No financial metrics, outcomes, or specific details on strategic transactions were disclosed.
- ·Registrant details: Nevada incorporation, Commission File Number 000-56587, IRS Employer I.D. No. 87-4125972.
- ·Emerging growth company status confirmed.
- ·Principal executive offices: 8211 E Regal Place, Tulsa, OK 74133; Phone: (918) 994-0693.
25-03-2026
Mission Financial Group, LLC filed its initial 13F-HR on March 25, 2026, disclosing $107.3M in equity holdings as of December 31, 2021 (Q4 FY21), across 143 positions with a focus on ETFs and large-cap tech stocks. Top holdings include Vanguard Total Stock Market ETF ($7.1M, 21,085 shares, flat QoQ), Apple Inc. ($4.6M, +12.5% shares QoQ), and Microsoft Corp. ($3.2M, +20.1% shares QoQ), reflecting buys in key tech names. However, positions like Boeing Co. (2,045 shares, flat QoQ) and Bank of America Corp. (4,994 shares, flat QoQ) showed no change, while the portfolio added new positions such as iShares 0-3 Month Treasury ETF.
- ·State of incorporation: NV
- ·Business address: 1240 Ala Moana Blvd, Suite 530, Honolulu, HI 96814
- ·Initial filing submission for Q4 2021
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)